自由君
2020-09-16
这篇文章不错,转发给大家看看
There are seven coronavirus vaccine candidates being tested in the U.S. -- here's where they stand
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":972632481,"tweetId":"972632481","gmtCreate":1600199728243,"gmtModify":1703820725001,"author":{"id":3547114025989487,"authorId":3547114025989487,"authorIdStr":"3547114025989487","name":"自由君","avatar":"https://static.tigerbbs.com/f249506f773b7df167d4defbae98dca7","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>这篇文章不错,转发给大家看看</p></body></html>","htmlText":"<html><head></head><body><p>这篇文章不错,转发给大家看看</p></body></html>","text":"这篇文章不错,转发给大家看看","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/972632481","repostId":2066210025,"repostType":2,"repost":{"id":"2066210025","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1599586620,"share":"https://www.laohu8.com/m/news/2066210025?lang=&edition=full","pubTime":"2020-09-09 01:37","market":"us","language":"en","title":"There are seven coronavirus vaccine candidates being tested in the U.S. -- here's where they stand","url":"https://stock-news.laohu8.com/highlight/detail?id=2066210025","media":"Dow Jones","summary":"MW UPDATE: There are seven coronavirus vaccine candidates being tested in the U.S. -- here's where t","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW UPDATE: There are seven coronavirus vaccine candidates being tested in the U.S. -- here's where they stand\n</p>\n<p>\n By Jaimy Lee \n</p>\n<p>\n At least three of the still investigational vaccines have moved into Phase 3 clinical trials \n</p>\n<p>\n The race to develop a safe and effective COVID-19 vaccine is well under way, setting the stage to bring to market the fastest vaccine in history. \n</p>\n<p>\n There are dozens of coronavirus vaccines in development, primarily in the preclinical phase when they are tested on animals. In the U.S., there are seven vaccine candidates that have moved into clinical trials with human participants, including three that have moved into the crucial Phase 3 development phase. \n</p>\n<p>\n The first and second phases of clinical studies are primarily conducted to test for safety, while the third and final stage is used to determine whether the vaccines are efficacious and can prevent infection among participants. At that point, the vaccine makers will decide when to pursue an emergency use authorization from the Food and Drug Administration and/or a full approval. The majority of the vaccines in development have received funding from the U.S. government, either to help support clinical development or pay for manufacturing and distribution of the vaccines as part of the Trump administration's Operation Warp Speed program. \n</p>\n<p>\n MarketWatch will update this tally as the vaccines move through development. \n</p>\n<p>\n Vaccines that have entered Phase 3 trials in the U.S. (cited in alphabetical order, by company name): \n</p>\n<p>\n AstraZeneca, in partnership with the University of Oxford \n</p>\n<p>\n Year-to-date stock performance:(AZN.LN) (AZN.LN) Up 7.8% \n</p>\n<p>\n Name: AZD1222 \n</p>\n<p>\n Type: Vector-based \n</p>\n<p>\n Phase 1/2: Data from the Phase 1/2 trial, which is being conducted in the U.K., was published July 20 in The Lancet neutralizing antibody responses in 91% of 35 patients when using <a href=\"https://laohu8.com/S/AONE.U\">one</a> test and 100% of 35 patients when using a different test. \n</p>\n<p>\n Phase 3: This trial, which will be held in the U.S., is expected to enroll up to 30,000 participants. (Late-stage studies are also being conducted in Brazil, and South Africa, and the U.K.) Data is expected by the end of the year. \n</p>\n<p>\n Clinical development and manufacturing funding from the U.S. government: up to $1.2 billion \n</p>\n<p>\n U.S. dose promise: 300 million doses \n</p>\n<p>\n Dosing: 2 doses \n</p>\n<p>\n BioNTech and Pfizer Inc. \n</p>\n<p>\n Year-to-date stock performances: BioNTech<a href=\"https://laohu8.com/S/BNTX\">$(BNTX)$</a>, up 75.0%; Pfizer<a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a>, down 8.3%. \n</p>\n<p>\n Name: BNT162b2 \n</p>\n<p>\n Type: mRNA \n</p>\n<p>\n Phase 1: The companies published preliminary data on July 1 for BNT162b1 as a preprint was published on Aug. 28 for BNT162b2 that found this candidate produced similar levels of antibodies but participants reported fewer reactions. \n</p>\n<p>\n This trial is expected to focus on BNT162b2. It is expected to enroll up to 30,000 participants in Argentina, Brazil, and the U.S. \n</p>\n<p>\n Manufacturing funding from the U.S. government: $1.95 billion \n</p>\n<p>\n U.S. dose promise: 100 million doses, with option to buy up to 500 million more doses \n</p>\n<p>\n Dosing: 2 doses \n</p>\n<p>\n Moderna Inc. \n</p>\n<p>\n Year-to-date stock performance:<a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> Up 187.8% \n</p>\n<p>\n Name: mRNA-1273 \n</p>\n<p>\n Type: mRNA \n</p>\n<p>\n Phase 1 . Moderna's vaccine candidate elicited neutralizing antibodies in all 45 participants in this trial, which was conducted in the U.S. in partnership with the National Institute of Allergy and Infectious Diseases. \n</p>\n<p>\n Phase 2a : This study closed enrollment of 600 participants on July 8. This trial is also focused on the U.S. \n</p>\n<p>\n Phase 3 : This study is expected to complete enrollment of up to 30,000 people sometime in September. \n</p>\n<p>\n R&D funding from BARDA: $955 million \n</p>\n<p>\n Supply funding from the U.S. government: Up to $1.525 billion \n</p>\n<p>\n U.S. dose promise: 100 million, with option to acquire up 400 million additional doses \n</p>\n<p>\n Dosing: 2 doses \n</p>\n<p>\n Vaccines that have entered Phase 1 and 2 trials in the U.S. (cited in alphabetical order, by company name): \n</p>\n<p>\n <a href=\"https://laohu8.com/S/INO\">Inovio Pharmaceuticals Inc</a>. \n</p>\n<p>\n Year-to-date stock performance:(INO)up 191.2% \n</p>\n<p>\n Name: INO-4800 \n</p>\n<p>\n Type: DNA \n</p>\n<p>\n Phase 1 on June; it has not yet shared the full data but has submitted the results for publication in a peer-reviewed medical journal. The trial is being conducted in the U.S. \n</p>\n<p>\n Phase 2/3: Inovio said Sept. 8 it plans to launch this phase of the study in September, if it is given the go-ahead by the FDA. \n</p>\n<p>\n U.S. government funding: It received $71 million from the Department of Defense to make and buy the devices that will be used to dispense the company's vaccine if it is authorized or approved. \n</p>\n<p>\n Johnson & Johnson \n</p>\n<p>\n Year-to-date stock performance:<a href=\"https://laohu8.com/S/JNJ\">$(JNJ)$</a> Up 1.2% \n</p>\n<p>\n Name: Ad26. COV2. S \n</p>\n<p>\n Type: Vector-based \n</p>\n<p>\n Phase 1/2a in the second half of July, with a goal of enrolling 1,045 adults in Belgium and the U.S. \n</p>\n<p>\n Phase 3: It plans to launch this trial in September. \n</p>\n<p>\n R&D funding from BARDA: $456 million \n</p>\n<p>\n U.S. government funding for manufacturing and delivery:More than $1 billion \n</p>\n<p>\n U.S. dose promise: 100 million doses, with option to buy up to 200 million additional doses \n</p>\n<p>\n Novavax Inc. \n</p>\n<p>\n Year-to-date stock performance:<a href=\"https://laohu8.com/S/NVAX\">$(NVAX)$</a> Up 2,167.6% \n</p>\n<p>\n Name: NVX-CoV2373 \n</p>\n<p>\n Type: Protein subunit \n</p>\n<p>\n Phase 1: . \n</p>\n<p>\n Phase 1/2: The second phase of the Phase 1/2 trial started in August and will be conducted in Australia and the U.S. \n</p>\n<p>\n Phase 3: TBD \n</p>\n<p>\n Clinical development and manufacturing funding from the U.S. government:$1.6 billion \n</p>\n<p>\n U.S. dose promise: 100 million doses \n</p>\n<pre><table><tbody><tr><td></td><td>Sanofi</td><td>in combination with GlaxoSmithKline's (TICKER:GSK) (TICKER:UK:GSK)</td><td>adjuvant technology </td></tr></tbody></table></pre>\n<p>\n Companies: \n</p>\n<p>\n Year-to-date stock performance: Sanofi (SAN.FR)(SAN.FR) Up 0.6%. \n</p>\n<p>\n Name: TBD \n</p>\n<p>\n Type: Protein-based \n</p>\n<p>\n Phase 1/2 study: The trial was initiated Sept. 3 , with a goal of enrolling 440 adults in the U.S. Results are expected in December. \n</p>\n<p>\n Phase 3: This study is expected to launch by the \"end of 2020.\" \n</p>\n<p>\n Clinical development and manufacturing funding from the U.S. government: Up to $2.1 billion \n</p>\n<p>\n U.S. dose promise: Up to 100 million doses, with option to buy up to 500 million doses \n</p>\n<pre><table><tbody><tr><td>Sources: Company websites, federal data, the World Health Organization, RBC Capital Markets </td></tr></tbody></table></pre>\n<p>\n -Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n (END) Dow Jones Newswires\n</p>\n<p>\n September 08, 2020 13:37 ET (17:37 GMT)\n</p>\n<p>\n Copyright (c) 2020 Dow Jones & Company, Inc.\n</p>\n</font></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>There are seven coronavirus vaccine candidates being tested in the U.S. -- here's where they stand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThere are seven coronavirus vaccine candidates being tested in the U.S. -- here's where they stand\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2020-09-09 01:37</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW UPDATE: There are seven coronavirus vaccine candidates being tested in the U.S. -- here's where they stand\n</p>\n<p>\n By Jaimy Lee \n</p>\n<p>\n At least three of the still investigational vaccines have moved into Phase 3 clinical trials \n</p>\n<p>\n The race to develop a safe and effective COVID-19 vaccine is well under way, setting the stage to bring to market the fastest vaccine in history. \n</p>\n<p>\n There are dozens of coronavirus vaccines in development, primarily in the preclinical phase when they are tested on animals. In the U.S., there are seven vaccine candidates that have moved into clinical trials with human participants, including three that have moved into the crucial Phase 3 development phase. \n</p>\n<p>\n The first and second phases of clinical studies are primarily conducted to test for safety, while the third and final stage is used to determine whether the vaccines are efficacious and can prevent infection among participants. At that point, the vaccine makers will decide when to pursue an emergency use authorization from the Food and Drug Administration and/or a full approval. The majority of the vaccines in development have received funding from the U.S. government, either to help support clinical development or pay for manufacturing and distribution of the vaccines as part of the Trump administration's Operation Warp Speed program. \n</p>\n<p>\n MarketWatch will update this tally as the vaccines move through development. \n</p>\n<p>\n Vaccines that have entered Phase 3 trials in the U.S. (cited in alphabetical order, by company name): \n</p>\n<p>\n AstraZeneca, in partnership with the University of Oxford \n</p>\n<p>\n Year-to-date stock performance:(AZN.LN) (AZN.LN) Up 7.8% \n</p>\n<p>\n Name: AZD1222 \n</p>\n<p>\n Type: Vector-based \n</p>\n<p>\n Phase 1/2: Data from the Phase 1/2 trial, which is being conducted in the U.K., was published July 20 in The Lancet neutralizing antibody responses in 91% of 35 patients when using <a href=\"https://laohu8.com/S/AONE.U\">one</a> test and 100% of 35 patients when using a different test. \n</p>\n<p>\n Phase 3: This trial, which will be held in the U.S., is expected to enroll up to 30,000 participants. (Late-stage studies are also being conducted in Brazil, and South Africa, and the U.K.) Data is expected by the end of the year. \n</p>\n<p>\n Clinical development and manufacturing funding from the U.S. government: up to $1.2 billion \n</p>\n<p>\n U.S. dose promise: 300 million doses \n</p>\n<p>\n Dosing: 2 doses \n</p>\n<p>\n BioNTech and Pfizer Inc. \n</p>\n<p>\n Year-to-date stock performances: BioNTech<a href=\"https://laohu8.com/S/BNTX\">$(BNTX)$</a>, up 75.0%; Pfizer<a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a>, down 8.3%. \n</p>\n<p>\n Name: BNT162b2 \n</p>\n<p>\n Type: mRNA \n</p>\n<p>\n Phase 1: The companies published preliminary data on July 1 for BNT162b1 as a preprint was published on Aug. 28 for BNT162b2 that found this candidate produced similar levels of antibodies but participants reported fewer reactions. \n</p>\n<p>\n This trial is expected to focus on BNT162b2. It is expected to enroll up to 30,000 participants in Argentina, Brazil, and the U.S. \n</p>\n<p>\n Manufacturing funding from the U.S. government: $1.95 billion \n</p>\n<p>\n U.S. dose promise: 100 million doses, with option to buy up to 500 million more doses \n</p>\n<p>\n Dosing: 2 doses \n</p>\n<p>\n Moderna Inc. \n</p>\n<p>\n Year-to-date stock performance:<a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> Up 187.8% \n</p>\n<p>\n Name: mRNA-1273 \n</p>\n<p>\n Type: mRNA \n</p>\n<p>\n Phase 1 . Moderna's vaccine candidate elicited neutralizing antibodies in all 45 participants in this trial, which was conducted in the U.S. in partnership with the National Institute of Allergy and Infectious Diseases. \n</p>\n<p>\n Phase 2a : This study closed enrollment of 600 participants on July 8. This trial is also focused on the U.S. \n</p>\n<p>\n Phase 3 : This study is expected to complete enrollment of up to 30,000 people sometime in September. \n</p>\n<p>\n R&D funding from BARDA: $955 million \n</p>\n<p>\n Supply funding from the U.S. government: Up to $1.525 billion \n</p>\n<p>\n U.S. dose promise: 100 million, with option to acquire up 400 million additional doses \n</p>\n<p>\n Dosing: 2 doses \n</p>\n<p>\n Vaccines that have entered Phase 1 and 2 trials in the U.S. (cited in alphabetical order, by company name): \n</p>\n<p>\n <a href=\"https://laohu8.com/S/INO\">Inovio Pharmaceuticals Inc</a>. \n</p>\n<p>\n Year-to-date stock performance:(INO)up 191.2% \n</p>\n<p>\n Name: INO-4800 \n</p>\n<p>\n Type: DNA \n</p>\n<p>\n Phase 1 on June; it has not yet shared the full data but has submitted the results for publication in a peer-reviewed medical journal. The trial is being conducted in the U.S. \n</p>\n<p>\n Phase 2/3: Inovio said Sept. 8 it plans to launch this phase of the study in September, if it is given the go-ahead by the FDA. \n</p>\n<p>\n U.S. government funding: It received $71 million from the Department of Defense to make and buy the devices that will be used to dispense the company's vaccine if it is authorized or approved. \n</p>\n<p>\n Johnson & Johnson \n</p>\n<p>\n Year-to-date stock performance:<a href=\"https://laohu8.com/S/JNJ\">$(JNJ)$</a> Up 1.2% \n</p>\n<p>\n Name: Ad26. COV2. S \n</p>\n<p>\n Type: Vector-based \n</p>\n<p>\n Phase 1/2a in the second half of July, with a goal of enrolling 1,045 adults in Belgium and the U.S. \n</p>\n<p>\n Phase 3: It plans to launch this trial in September. \n</p>\n<p>\n R&D funding from BARDA: $456 million \n</p>\n<p>\n U.S. government funding for manufacturing and delivery:More than $1 billion \n</p>\n<p>\n U.S. dose promise: 100 million doses, with option to buy up to 200 million additional doses \n</p>\n<p>\n Novavax Inc. \n</p>\n<p>\n Year-to-date stock performance:<a href=\"https://laohu8.com/S/NVAX\">$(NVAX)$</a> Up 2,167.6% \n</p>\n<p>\n Name: NVX-CoV2373 \n</p>\n<p>\n Type: Protein subunit \n</p>\n<p>\n Phase 1: . \n</p>\n<p>\n Phase 1/2: The second phase of the Phase 1/2 trial started in August and will be conducted in Australia and the U.S. \n</p>\n<p>\n Phase 3: TBD \n</p>\n<p>\n Clinical development and manufacturing funding from the U.S. government:$1.6 billion \n</p>\n<p>\n U.S. dose promise: 100 million doses \n</p>\n<pre><table><tbody><tr><td></td><td>Sanofi</td><td>in combination with GlaxoSmithKline's (TICKER:GSK) (TICKER:UK:GSK)</td><td>adjuvant technology </td></tr></tbody></table></pre>\n<p>\n Companies: \n</p>\n<p>\n Year-to-date stock performance: Sanofi (SAN.FR)(SAN.FR) Up 0.6%. \n</p>\n<p>\n Name: TBD \n</p>\n<p>\n Type: Protein-based \n</p>\n<p>\n Phase 1/2 study: The trial was initiated Sept. 3 , with a goal of enrolling 440 adults in the U.S. Results are expected in December. \n</p>\n<p>\n Phase 3: This study is expected to launch by the \"end of 2020.\" \n</p>\n<p>\n Clinical development and manufacturing funding from the U.S. government: Up to $2.1 billion \n</p>\n<p>\n U.S. dose promise: Up to 100 million doses, with option to buy up to 500 million doses \n</p>\n<pre><table><tbody><tr><td>Sources: Company websites, federal data, the World Health Organization, RBC Capital Markets </td></tr></tbody></table></pre>\n<p>\n -Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n (END) Dow Jones Newswires\n</p>\n<p>\n September 08, 2020 13:37 ET (17:37 GMT)\n</p>\n<p>\n Copyright (c) 2020 Dow Jones & Company, Inc.\n</p>\n</font></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克","BNTX":"BioNTech SE","AZN":"阿斯利康","MRNA":"Moderna, Inc.","GSK.UK":"葛兰素史克","SNY":"赛诺菲安万特","JNJ":"强生","INO":"伊诺维奥制药","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药"},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2066210025","content_text":"MW UPDATE: There are seven coronavirus vaccine candidates being tested in the U.S. -- here's where they stand\n\n\n By Jaimy Lee \n\n\n At least three of the still investigational vaccines have moved into Phase 3 clinical trials \n\n\n The race to develop a safe and effective COVID-19 vaccine is well under way, setting the stage to bring to market the fastest vaccine in history. \n\n\n There are dozens of coronavirus vaccines in development, primarily in the preclinical phase when they are tested on animals. In the U.S., there are seven vaccine candidates that have moved into clinical trials with human participants, including three that have moved into the crucial Phase 3 development phase. \n\n\n The first and second phases of clinical studies are primarily conducted to test for safety, while the third and final stage is used to determine whether the vaccines are efficacious and can prevent infection among participants. At that point, the vaccine makers will decide when to pursue an emergency use authorization from the Food and Drug Administration and/or a full approval. The majority of the vaccines in development have received funding from the U.S. government, either to help support clinical development or pay for manufacturing and distribution of the vaccines as part of the Trump administration's Operation Warp Speed program. \n\n\n MarketWatch will update this tally as the vaccines move through development. \n\n\n Vaccines that have entered Phase 3 trials in the U.S. (cited in alphabetical order, by company name): \n\n\n AstraZeneca, in partnership with the University of Oxford \n\n\n Year-to-date stock performance:(AZN.LN) (AZN.LN) Up 7.8% \n\n\n Name: AZD1222 \n\n\n Type: Vector-based \n\n\n Phase 1/2: Data from the Phase 1/2 trial, which is being conducted in the U.K., was published July 20 in The Lancet neutralizing antibody responses in 91% of 35 patients when using one test and 100% of 35 patients when using a different test. \n\n\n Phase 3: This trial, which will be held in the U.S., is expected to enroll up to 30,000 participants. (Late-stage studies are also being conducted in Brazil, and South Africa, and the U.K.) Data is expected by the end of the year. \n\n\n Clinical development and manufacturing funding from the U.S. government: up to $1.2 billion \n\n\n U.S. dose promise: 300 million doses \n\n\n Dosing: 2 doses \n\n\n BioNTech and Pfizer Inc. \n\n\n Year-to-date stock performances: BioNTech$(BNTX)$, up 75.0%; Pfizer$(PFE)$, down 8.3%. \n\n\n Name: BNT162b2 \n\n\n Type: mRNA \n\n\n Phase 1: The companies published preliminary data on July 1 for BNT162b1 as a preprint was published on Aug. 28 for BNT162b2 that found this candidate produced similar levels of antibodies but participants reported fewer reactions. \n\n\n This trial is expected to focus on BNT162b2. It is expected to enroll up to 30,000 participants in Argentina, Brazil, and the U.S. \n\n\n Manufacturing funding from the U.S. government: $1.95 billion \n\n\n U.S. dose promise: 100 million doses, with option to buy up to 500 million more doses \n\n\n Dosing: 2 doses \n\n\n Moderna Inc. \n\n\n Year-to-date stock performance:$(MRNA)$ Up 187.8% \n\n\n Name: mRNA-1273 \n\n\n Type: mRNA \n\n\n Phase 1 . Moderna's vaccine candidate elicited neutralizing antibodies in all 45 participants in this trial, which was conducted in the U.S. in partnership with the National Institute of Allergy and Infectious Diseases. \n\n\n Phase 2a : This study closed enrollment of 600 participants on July 8. This trial is also focused on the U.S. \n\n\n Phase 3 : This study is expected to complete enrollment of up to 30,000 people sometime in September. \n\n\n R&D funding from BARDA: $955 million \n\n\n Supply funding from the U.S. government: Up to $1.525 billion \n\n\n U.S. dose promise: 100 million, with option to acquire up 400 million additional doses \n\n\n Dosing: 2 doses \n\n\n Vaccines that have entered Phase 1 and 2 trials in the U.S. (cited in alphabetical order, by company name): \n\n\nInovio Pharmaceuticals Inc. \n\n\n Year-to-date stock performance:(INO)up 191.2% \n\n\n Name: INO-4800 \n\n\n Type: DNA \n\n\n Phase 1 on June; it has not yet shared the full data but has submitted the results for publication in a peer-reviewed medical journal. The trial is being conducted in the U.S. \n\n\n Phase 2/3: Inovio said Sept. 8 it plans to launch this phase of the study in September, if it is given the go-ahead by the FDA. \n\n\n U.S. government funding: It received $71 million from the Department of Defense to make and buy the devices that will be used to dispense the company's vaccine if it is authorized or approved. \n\n\n Johnson & Johnson \n\n\n Year-to-date stock performance:$(JNJ)$ Up 1.2% \n\n\n Name: Ad26. COV2. S \n\n\n Type: Vector-based \n\n\n Phase 1/2a in the second half of July, with a goal of enrolling 1,045 adults in Belgium and the U.S. \n\n\n Phase 3: It plans to launch this trial in September. \n\n\n R&D funding from BARDA: $456 million \n\n\n U.S. government funding for manufacturing and delivery:More than $1 billion \n\n\n U.S. dose promise: 100 million doses, with option to buy up to 200 million additional doses \n\n\n Novavax Inc. \n\n\n Year-to-date stock performance:$(NVAX)$ Up 2,167.6% \n\n\n Name: NVX-CoV2373 \n\n\n Type: Protein subunit \n\n\n Phase 1: . \n\n\n Phase 1/2: The second phase of the Phase 1/2 trial started in August and will be conducted in Australia and the U.S. \n\n\n Phase 3: TBD \n\n\n Clinical development and manufacturing funding from the U.S. government:$1.6 billion \n\n\n U.S. dose promise: 100 million doses \n\nSanofiin combination with GlaxoSmithKline's (TICKER:GSK) (TICKER:UK:GSK)adjuvant technology \n\n Companies: \n\n\n Year-to-date stock performance: Sanofi (SAN.FR)(SAN.FR) Up 0.6%. \n\n\n Name: TBD \n\n\n Type: Protein-based \n\n\n Phase 1/2 study: The trial was initiated Sept. 3 , with a goal of enrolling 440 adults in the U.S. Results are expected in December. \n\n\n Phase 3: This study is expected to launch by the \"end of 2020.\" \n\n\n Clinical development and manufacturing funding from the U.S. government: Up to $2.1 billion \n\n\n U.S. dose promise: Up to 100 million doses, with option to buy up to 500 million doses \n\nSources: Company websites, federal data, the World Health Organization, RBC Capital Markets \n\n -Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com \n\n\n \n\n\n (END) Dow Jones Newswires\n\n\n September 08, 2020 13:37 ET (17:37 GMT)\n\n\n Copyright (c) 2020 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1087,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":27,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/972632481"}
精彩评论